摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-3-苯氧基吡咯烷盐酸盐 | 931409-72-2

中文名称
(S)-3-苯氧基吡咯烷盐酸盐
中文别名
——
英文名称
(3S)-3-phenoxypyrrolidine hydrochloride
英文别名
(S)-3-phenoxypyrrolidine hydrochloride;(3S)-3-phenoxypyrrolidine;hydrochloride
(S)-3-苯氧基吡咯烷盐酸盐化学式
CAS
931409-72-2
化学式
C10H13NO*ClH
mdl
——
分子量
199.68
InChiKey
NHLZTNBPPGIUMZ-PPHPATTJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.85
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    21.3
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 危险性防范说明:
    P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
  • 危险性描述:
    H315,H319

SDS

SDS:2f84ff145953b64d06d171e01c9bcb7d
查看

反应信息

  • 作为反应物:
    描述:
    (S)-3-苯氧基吡咯烷盐酸盐5-oxo-2,2-diphenylpentanenitrile三乙胺溶剂黄146三乙酰氧基硼氢化钠 作用下, 以 二氯甲烷 为溶剂, 反应 5.5h, 以47%的产率得到5-[(3S)-3-phenoxypyrrolidin-1-yl]-2,2-diphenylpentanenitrile
    参考文献:
    名称:
    Inhalation by Design: Novel Tertiary Amine Muscarinic M3 Receptor Antagonists with Slow Off-Rate Binding Kinetics for Inhaled Once-Daily Treatment of Chronic Obstructive Pulmonary Disease
    摘要:
    A novel tertiary amine series of potent muscarinic M-3 receptor antagonists are described that exhibit potential as inhaled long-acting bronchodilators for the treatment of chronic obstructive pulmonary disease. Geminal dimethyl functionality present in this series of compounds confers very long dissociative half-life (slow off-rate) from the M-3 receptor that mediates very long-lasting smooth muscle relaxation in guinea pig tracheal strips. Optimization of pharmacokinetic properties was achieved by combining rapid oxidative clearance with targeted introduction of a phenolic moiety to secure rapid glucuronidation. Together, these attributes minimize systemic exposure following inhalation, mitigate potential drug-drug interactions, and reduce systemically mediated adverse events. Compound 47 (PP-3635659) is identified as a Phase II clinical candidate from this series with in vivo duration of action studies confirming its potential for once-daily use in humans.
    DOI:
    10.1021/jm200884j
  • 作为产物:
    描述:
    (S)-tert-butyl 3-phenoxypyrrolidine-1-carboxylate盐酸 作用下, 以 1,4-二氧六环 为溶剂, 反应 2.0h, 以100%的产率得到(S)-3-苯氧基吡咯烷盐酸盐
    参考文献:
    名称:
    WO2007/34325
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • [EN] TRIAZINE-OXADIAZOLES<br/>[FR] TRIAZINE-OXADIAZOLES
    申请人:NOVARTIS AG
    公开号:WO2012035023A1
    公开(公告)日:2012-03-22
    The invention relates to new derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of chronic pain.
    这项发明涉及公式(I)的新衍生物,其中取代基如规范中所定义;制备这种衍生物的方法;包括这种衍生物的药物组合物;将这种衍生物用作药物;将这种衍生物用于治疗慢性疼痛。
  • Carboxamide derivatives as muscarinic receptor antagonists
    申请人:Glossop Alan Paul
    公开号:US20070105831A1
    公开(公告)日:2007-05-10
    The invention relates to compounds of formula processes and intermediates for their preparation, their use as muscarinic antagonists and pharmaceutical composition containing them.
    本发明涉及具有下列公式的化合物、其制备方法和中间体,以及包含它们的抗胆碱能药物组合物。
  • Carboxamide Derivatives As Muscarinic Receptor Antagonists
    申请人:Glossop Paul Alan
    公开号:US20100029720A1
    公开(公告)日:2010-02-04
    The invention relates to compounds of formula processes and intermediates for their preparation, their use as muscarinic antagonists and pharmaceutical composition containing them.
    本发明涉及具有以下式的化合物,以及制备它们的过程和中间体,它们作为毒蕈碱受体拮抗剂的用途和包含它们的制药组合物。
  • Triazine-oxadiazoles
    申请人:BARKER Oliver
    公开号:US20140051676A1
    公开(公告)日:2014-02-20
    The invention relates to new derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of chronic pain.
    该发明涉及公式(I)的新衍生物,其中取代基如规范中所定义;制备这种衍生物的方法;包含这种衍生物的药物组合物;这种衍生物作为药物;这种衍生物用于治疗慢性疼痛。
  • WO2021018857A5
    申请人:——
    公开号:WO2021018857A5
    公开(公告)日:2023-07-14
查看更多